Get started
Author

Jaime Carungcong

Mapping the human genetic architecture of COVID-19
2021 · COVID-19 Host Genetics Initiative, COVID-19 Host Genetics InitiativeLeadership, et al. · Nature · 983
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Eugenia Abaleke, Mustafa Abbas, et al. · The Lancet · 533
PDF
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 493
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 369
Whole-genome sequencing reveals host factors underlying critical COVID-19
2022 · Athanasios Kousathanas, Erola Pairo-Castineira, et al. · Nature · 326
PDF
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 324
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 290
Effect of Lower Tidal Volume Ventilation Facilitated by Extracorporeal Carbon Dioxide Removal vs Standard Care Ventilation on 90-Day Mortality in Patients With Acute Hypoxemic Respiratory Failure
2021 · James J. McNamee, Michael A. Gillies, et al. · JAMA · 227
PDF
GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19
2023 · Erola Pairo-Castineira, Konrad Rawlik, et al. · Nature · 224
PDF
Hypotension-Avoidance Versus Hypertension-Avoidance Strategies in Noncardiac Surgery
2023 · Maura Marcucci, Thomas W. Painter, et al. · Annals of Internal Medicine · 173
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 129
A second update on mapping the human genetic architecture of COVID-19
2023 · The COVID-19 Host Genetics Initiative, Leadership, et al. · Nature · 118
PDF
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
2022 · Simeng Lin, Nicholas A. Kennedy, et al. · Nature Communications · 96
PDF
Effect of High-Flow Nasal Cannula Therapy vs Continuous Positive Airway Pressure Therapy on Liberation From Respiratory Support in Acutely Ill Children Admitted to Pediatric Critical Care Units
2022 · Padmanabhan Ramnarayan, Alvin Richards-Belle, et al. · JAMA · 74
PDF
Initiation of continuous renal replacement therapy versus intermittent hemodialysis in critically ill patients with severe acute kidney injury: a secondary analysis of STARRT-AKI trial
2023 · Ron Wald, Stephane Gaudry, et al. · Intensive Care Medicine · 71
PDF
Intraoperative positive end-expiratory pressure and postoperative pulmonary complications: a patient-level meta-analysis of three randomised clinical trials
2022 · Niklas S. Campos, Thomas Bluth, et al. · British Journal of Anaesthesia · 68
INHALE WP3, a multicentre, open-label, pragmatic randomised controlled trial assessing the impact of rapid, ICU-based, syndromic PCR, versus standard-of-care on antibiotic stewardship and clinical outcomes in hospital-acquired and ventilator-associated pneumonia
2025 · Virve I. Enne, Susan Stirling, et al. · Intensive Care Medicine · 52
PDF
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41
PDF
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39
PDF
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
2022 · Zhigang Liu, Kaixing Le, et al. · ˜The œLancet. Gastroenterology & hepatology · 36
Impact of renal-replacement therapy strategies on outcomes for patients with chronic kidney disease: a secondary analysis of the STARRT-AKI trial
2022 · Sean M. Bagshaw, Ary Serpa Neto, et al. · Intensive Care Medicine · 29
A Bayesian reanalysis of the Standard versus Accelerated Initiation of Renal-Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial
2022 · Fernando G. Zampieri, Bruno R. da Costa, et al. · Critical Care · 21
PDF
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases · 12
PDF
Stratified analyses refine association between TLR7 rare variants and severe COVID-19
2024 · Jannik Boos, Caspar I. van der Made, et al. · Human Genetics and Genomics Advances · 12
PDF
Cost-effectiveness of rapid, ICU-based, syndromic PCR in hospital-acquired pneumonia: analysis of the INHALE WP3 multi-centre RCT
2025 · Adam P. Wagner, Virve I. Enne, et al. · Critical Care · 9
PDF
Works count: 35
Citation count: 4,764
H-index: 21
I10-index: 24
Year
Topic
Type